Neoplasms Clinical Trial
Official title:
Pilot Yoga Intervention to Improve Pediatric Cancer Patients' Sleep & Life Quality and Parents' Well-Being
| Verified date | February 2017 |
| Source | Connecticut Children's Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The proposed project will examine feasibility and preliminary efficacy of a yoga intervention in the pediatric oncology unit at Connecticut Children's Medical Center (CCMC) and includes two parts: (1) a survey of children and parents regarding preferences (e.g., convenient days/times), experiences and expectations regarding yoga (including barriers and positive expectancies) and (2) an eight week clinical trial of a yoga intervention in 10 pairs of children and parents.
| Status | Completed |
| Enrollment | 23 |
| Est. completion date | January 2017 |
| Est. primary completion date | October 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 8 Years to 18 Years |
| Eligibility |
Inclusion Criteria: - Parents and children (ages 8-18) undergoing treatment (chemotherapy and/or radiation therapy) for cancer. - Cancer diagnosis, between the ages of 8-18 year, English speaking, and medically cleared to participate in yoga. - Parents will be eligible if they are over 18 years old, English speaking, and physically able to participate in yoga. Exclusion Criteria: - Children and parents not meeting inclusion criteria |
| Country | Name | City | State |
|---|---|---|---|
| United States | Connecticut Children's Medical Center | Hartford | Connecticut |
| Lead Sponsor | Collaborator |
|---|---|
| Connecticut Children's Medical Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Feasibility of yoga intervention, perceived barriers/solutions | The data will be assessed on perceived barriers/solutions. | Change from baseline barriers/solutions at 8 weeks post baseline visit | |
| Primary | Assess level of interest utlizing data from the Yoga satisfaction survey | Data will be assessed by level of interest utilizing data from the yoga satisfcation survey. Most responses will be on a Likert scale while some specific questions will be other formats (i.e. open ended questions). These questions will help to inform the intervention. | Data collected at baseline and 8 weeks post baseline visit | |
| Primary | Feasibility of yoga intervention, assessed by study accrual rates | Data will be assessed by accrual rates | Baseline and 8 weeks post baseline visit | |
| Primary | Feasibility of yoga intervention, assessed by study visit attendance | Data will be assessed by study visit attendance | Baseline and 8 weeks post baseline visit | |
| Primary | Feasibility of yoga intervention, assessed by study patient retention | Data will be assessed by the number of patients who remain in the study | Baseline and 8 weeks post baseline visit | |
| Primary | Feasibility of yoga intervention, assessed by institutional support | Data will be reviewed for evidence of institutional support | Baseline and 8 weeks post baseline visit | |
| Primary | Feasibility of yoga intervention, assessed by institutional commitment of resources. | Data will be reviewed for institutional resource commitment | Assessments are collected at baseline and 8 weeks post baseline visit | |
| Secondary | Improvement in sleep of Patient | Sleep will be assessed via diary of sleep and actigraphy | Assessments are collected at baseline and 8 weeks post baseline visit | |
| Secondary | Improvement in quality of life Patient | Quality of life will be assessed by PedsQL 4.0 and PedsQL 3.0 Cancer Module. | Assessments are collected at baseline and 8 weeks post baseline visit | |
| Secondary | Improvement in fatigue of Patient | Fatigue will be assessed by the Fatigue Scale (FS). The Fatigue Scale for children (FS-C) between 8-12 years and the Fatigue Scale for adolescent (FS-A) between 13-18 years. | Assessments are collected at baseline and 8 weeks post baseline visit | |
| Secondary | Improvement in quality of life of Parent | Parent quality of life will be assessed by the SF-12. | Assessments are collected at baseline and 8 weeks post baseline visit | |
| Secondary | Improvement in caregiver burden of Parent. | Caregiver burden will be assessed by the Zarit Caregiver Burden Index | Assessments are collected at baseline and 8 weeks post baseline visit |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
| Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
| Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
| Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |